Q32 Bio Inc. — Form SCHEDULE 13D/A
Filed July 20, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 22/100
What the filing says
OrbiMed Advisors LLC, OrbiMed Capital GP VII LLC, and OrbiMed Genesis GP LLC jointly filed Amendment No. 4 to their Schedule 13D statement dated July 16, 2026, concerning Q32 Bio Inc. common stock (par value $0.0001/share). The filing is a joint filing agreement executed July 20, 2026, signed by Carl L. Gordon as member of OrbiMed Advisors LLC. No specific changes to holdings, percentages, or transaction details are disclosed in this excerpt.
Why this rating
Procedural Schedule 13D amendment filing only; no substantive business changes, deal terms, or holdings data disclosed in excerpt. Routine disclosure.
See more from July 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.